NO20071953L - RNAi modulering av RSV, PIV og andre respiratoriske viruser og anvendelse derav - Google Patents

RNAi modulering av RSV, PIV og andre respiratoriske viruser og anvendelse derav

Info

Publication number
NO20071953L
NO20071953L NO20071953A NO20071953A NO20071953L NO 20071953 L NO20071953 L NO 20071953L NO 20071953 A NO20071953 A NO 20071953A NO 20071953 A NO20071953 A NO 20071953A NO 20071953 L NO20071953 L NO 20071953L
Authority
NO
Norway
Prior art keywords
rsv
piv
respiratory viruses
findings
present
Prior art date
Application number
NO20071953A
Other languages
English (en)
Norwegian (no)
Inventor
Sailen Barik
Original Assignee
Univ South Alabama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Alabama filed Critical Univ South Alabama
Publication of NO20071953L publication Critical patent/NO20071953L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20071953A 2004-10-22 2007-04-17 RNAi modulering av RSV, PIV og andre respiratoriske viruser og anvendelse derav NO20071953L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62155204P 2004-10-22 2004-10-22
US11/151,893 US7592322B2 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US11/151,976 US20060089324A1 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
PCT/US2005/038269 WO2006062596A2 (en) 2004-10-22 2005-10-21 RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF

Publications (1)

Publication Number Publication Date
NO20071953L true NO20071953L (no) 2007-05-18

Family

ID=36578352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071953A NO20071953L (no) 2004-10-22 2007-04-17 RNAi modulering av RSV, PIV og andre respiratoriske viruser og anvendelse derav

Country Status (12)

Country Link
US (2) US20060089324A1 (pt)
EP (1) EP1806968B1 (pt)
JP (1) JP5037349B2 (pt)
KR (1) KR101193825B1 (pt)
CN (1) CN101087527B (pt)
AU (1) AU2005314617B2 (pt)
BR (1) BRPI0517286A (pt)
CA (1) CA2584309A1 (pt)
MX (1) MX2007004692A (pt)
NO (1) NO20071953L (pt)
RU (1) RU2494745C2 (pt)
WO (1) WO2006062596A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
CN101119734B (zh) * 2005-01-07 2012-05-09 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2229459B1 (en) * 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
CA2732229C (en) * 2008-07-25 2023-10-17 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
JP2013521771A (ja) * 2010-03-08 2013-06-13 ノバルティス アーゲー 細胞内病原体について試験する方法
WO2012118911A1 (en) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US8916352B2 (en) * 2011-04-08 2014-12-23 Bio-Rad Laboratories, Inc. PCR reaction mixtures with decreased non-specific activity
US11163898B2 (en) * 2013-09-11 2021-11-02 Mimecast Services Ltd. Sharing artifacts in permission-protected archives
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
AU2015320409B2 (en) 2014-09-26 2019-03-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Virus-based expression vectors and uses thereof
MX2020003838A (es) 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
BR112021023594A2 (pt) 2019-05-28 2022-02-08 Selecta Biosciences Inc Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
US20250152599A1 (en) * 2020-03-13 2025-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd Anti-coronavirus effect and application of p14k inhibitor
EP4162050A1 (en) * 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses
WO2026063375A1 (ja) * 2024-09-20 2026-03-26 東亞合成株式会社 Rsv pタンパク質 rna配列に基づく新規二本鎖rna及びその利用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
AU6848396A (en) * 1995-10-17 1997-05-07 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
US20030124513A1 (en) * 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
US20030148928A1 (en) 2001-07-20 2003-08-07 Leonid Beigelman Enzymatic nucleic acid peptide conjugates
US20030203356A1 (en) * 2002-01-22 2003-10-30 The Cleveland Clinic Foundation RNase L activator-antisense complexes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
WO2004042002A2 (en) * 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
JP2006512906A (ja) * 2002-09-28 2006-04-20 マサチューセッツ インスティチュート オブ テクノロジー インフルエンザ治療剤
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
EP1562970A4 (en) * 2002-11-01 2006-04-12 Univ Pennsylvania COMPOSITIONS AND METHODS FOR SIRNAIL INHIBITION OF HIF-1 ALPHA
ATE477337T1 (de) * 2003-01-16 2010-08-15 Univ Pennsylvania Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
WO2004094345A2 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. Protected monomers
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾iRNA剤
WO2005056021A1 (en) * 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
CN101119734B (zh) * 2005-01-07 2012-05-09 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用

Also Published As

Publication number Publication date
CN101087527A (zh) 2007-12-12
CA2584309A1 (en) 2006-06-15
WO2006062596A3 (en) 2007-05-18
CN101087527B (zh) 2012-01-18
RU2494745C2 (ru) 2013-10-10
JP2008517940A (ja) 2008-05-29
EP1806968A2 (en) 2007-07-18
MX2007004692A (es) 2007-09-07
AU2005314617B2 (en) 2011-05-26
AU2005314617A1 (en) 2006-06-15
US20060089323A1 (en) 2006-04-27
KR20070106686A (ko) 2007-11-05
KR101193825B1 (ko) 2012-10-23
BRPI0517286A (pt) 2008-10-07
JP5037349B2 (ja) 2012-09-26
HK1114308A1 (en) 2008-10-31
RU2010139908A (ru) 2012-04-10
EP1806968B1 (en) 2012-12-05
US20060089324A1 (en) 2006-04-27
WO2006062596A2 (en) 2006-06-15
US7592322B2 (en) 2009-09-22
EP1806968A4 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
WO2006074346A3 (en) RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF
WO2006062596A3 (en) RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF
WO2004028471A3 (en) Influenza therapeutic
WO2009136979A3 (en) Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
EP2114449A4 (en) COMBINED HERPES SIMPLEX VIRUS SUBUNIT VACCINES AND APPLICATION PROCEDURES
NO20090438L (no) Hepatit C virus inhibitorer
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
WO2007053696A3 (en) Rnai inhibition of influenza virus replication
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
NO20072733L (no) Doseformer
EA200701097A1 (ru) Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами
WO2010047830A3 (en) Agents for hcv treatment
NO20090447L (no) Hepatittt C virusinhibitorer
WO2009098492A3 (en) Modulation of adenoviral tropism
NO20071924L (no) Vaksiner mot japansk ecefalittvirus og West Nile virus
WO2005028658A3 (en) Recombinant influenza vectors with a polii promoter and ribozymes
WO2008140557A3 (en) A method of predicting influenza outbreaks
EA201071086A1 (ru) Усовершенствованный способ получения вакцинных антигенов вируса гриппа
CY1112699T1 (el) Ηcv νs5β αναστολεις τυπου κυκλοπροπυλο συγχωνευμενης ινδολοβενζαζεπινης
WO2010011343A3 (en) Methods for treating viral disorders
TW200740458A (en) Vaccination against dengue virus infection
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2006091610A3 (en) Inhibitors of enveloped virus infectivity
DE602008006257D1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application